Type A and B3 thymoma and thymic carcinoma tissues were stained with antibodies to ALK, HER2, HER3, MET, phospho-mTOR, PDGFRA, PDGFRB, PD-L1, p16INK4A, PTEN and ROS1 to identify potential targets for therapy. Here, CDKN2A is linked to thymic carcinoma.